Boardroom
Posts
Countdown is on to jump on this megatrend ⏳

Countdown is on to jump on this megatrend ⏳

Traders take note

November 07, 2023

*Sponsored by Psycheceutical Bioscience

Hey Folks!

The countdown is on… Our newest partner in the Boardroom, Psycheceutical, just launched their public round of crowdfunding on November 1st. This means their Early Bird Discount will soon run out, so give this company – that is at the FOREFRONT of a potential TRILLION dollar industry – a deep dive ASAP.

With that, I strongly encourage you to listen to Zappy Zapolin, Founding Member, on why Psycheceutical is perfectly positioned and timed for the emerging psychedelic industry.

“We are witnessing a megatrend in the psychedelic medicine industry”
~ Zappy Zapolin

Stock traders’ ears will especially perk up when Zappy compares investing in the psychedelic industry to investing in pharma stocks in the 1920s and biotechs in the 1990s.

Why does this industry have such crazy potential? There’s a growing collection of research supporting the effectiveness of psychedelic medicines for treating a host of mental disorders like depression, anxiety, post-traumatic stress disorder, and addiction. In fact, Time calls the psychedelic industry this:

Yes…a TOP medical breakthrough!

Psychedelic treatments are growing in popularity as understanding of how and why they work improves. However, the trick for widespread public and medical acceptance seems to lie in the dosing...

That’s the domain of this TOP Biotech Startup of 2023 (as named by LifeSciences Review) – Psycheceutical!

According to my recent interview with CEO Chad Harman, the company is developing two state-of-the-art drug delivery technologies that enable the precise dosing required for the safe and effective treatment of depression, PTSD, anxiety, and a host of other mental health disorders.

And guess, what? The big dogs in the media are taking note!

I believe that the work that this company is doing is truly revolutionary. And right now, Psycheceutical is seeking investors to come alongside and share in their vision. Not only is it trading as BWVI on the OTC market, the company is conducting a Reg CF campaign through Wefunder to further its research and development. This gives favorable terms – better entry prices than buying shares on the exchange – to new investors.

So I urge you to do the following important things:

Watch my interview with Mr. Harman right here. There is a ton of useful information about the company’s progress, plans, and more.
Check out their investor presentation here.
Take a look at the company’s WeFunder page here for more details. The Early Bird Discount (25% discount to market) will run out soon.
Do your own due diligence.

Psycheceutical is operating in a market of 300 million plus people suffering from depression, addiction, PTSD and other mental disorders, and sadly this number only seems to be increasing (think of COVID, and now wars in Ukraine and Israel).

With the company well into its Phase 1 trials of its Neurodirect ketamine topical for the treatment of PTSD, and a minimum investment of only $250 required, NOW is the perfect time to hop on this train.

To YOUR success,

*Sponsored content. Like all investments, this investment involves substantial risk. Please see full disclosures below.

DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at https://ragingbull.com/paid-advertisement-disclaimer/.

ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (“Raging Bull”) seventy five hundred dollars in total to run advertisements enhancing public awareness of the company.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. Raging Bull strongly recommends you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this Advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Investing in the private companies discussed in this Advertisement is highly risky. There is currently no market for trading or liquidating the securities discussed in this Advertisement and there is no guarantee that a market will develop in the future. Readers of this Advertisement bear responsibility for their own investment research and decisions and should use information from this Advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money INVESTING OR trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.